Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B (Q59306519)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752878%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752878%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

1 reference

H Chi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752878%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

C Yim

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752878%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

P Arends

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752878%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

M Abu-Amara

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752878%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

A A van der Eijk

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752878%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

J J Feld

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752878%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

R J de Knegt

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752878%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

H L A Janssen

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752878%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

language of work or name

English

0 references

publication date

5 March 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752878%20AND%20SRC:MED&resulttype=core&format=json

Alimentary Pharmacology & Therapeutics

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752878%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752878%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752878%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

867-876

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752878%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

2 March 2020

cites work

1 reference

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

21 January 2018

1 reference

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

21 January 2018

1 reference

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

21 January 2018

1 reference

Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis.

21 January 2018

1 reference

Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis

21 January 2018

1 reference

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

Chronic hepatitis B: update 2009

21 January 2018

1 reference

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

Relapse of chronic hepatitis B after discontinuation of nucleos(t)ide analogs: is the glass half full or half empty?

21 January 2018

1 reference

Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.

21 January 2018

1 reference

Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss

21 January 2018

1 reference

Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir

21 January 2018

1 reference

Clinical performance of the novel DiaSorin LIAISON(®) XL murex: HBsAg Quant, HCV-Ab, HIV-Ab/Ag assays

21 January 2018

1 reference

Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients

21 January 2018

1 reference

Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients

21 January 2018

1 reference

The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment

21 January 2018

1 reference

Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/APT.13150

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752878%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference